SUNRISE, Fla., Aug. 30 /PRNewswire/ — Bioheart,
Inc. – (OTC Bulletin Board:
BHRT) The mission of the Cell Therapy Foundation is to improve
public health through the support of effective adult stem cell
research and education. The Foundation aims to promote basic and
applied knowledge, processes and cell therapies. As part of this
mission Cell Therapy Foundation provides updates concerning
advances in adult stem cell research. A recent initiative
tabulating clinical trials involving cell therapy identified
Bioheart’s MyoCell as one of only a few cell therapies that are
presently in the Phase III stage of clinical trials in the United
States. MyoCell has shown the ability to improve heart function in
patients suffering from heart failure.
At the Heart Failure Society of America Annual Meeting, Bioheart
presented interim results from their randomized, double blinded,
placebo controlled Phase II/III clinical trial called MARVEL. The
MARVEL study focused on treating significant scar tissue damage
caused from a previous heart attack in advanced heart failure
patients. The results were outstanding. MyoCell treated patients
improved 91.7 meters in the six minute walk test, while the placebo
patients declined 4 meters.
Dr. Warren Sherman, Lead Investigator of the MARVEL trial and
Director of Stem Cell Research and Regenerative Medicine at
Columbia University Medical Center stated, “The early positive
clinical results from Bioheart’s MyoCell are truly an example of
how far along adult stem cell research has come. We are very close
to proving the value of adult stem cell therapy for a major unmet
indication such as heart failure. This is very exciting to all of
us in the field.”
Bioheart’s MyoCell is a composition of immature myoblasts or
adult muscle stem cells derived from a biopsy of a patient’s thigh
muscle. This muscle biop
‘/>”/>
